Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 1104-1108

  Ita, Masamichi ^a,b   Halicka, H Dorota ^a   Tanaka, Toshiki ^a,c   Kurose, Akira ^a,d   Ardelt, Barbara ^a,e   Shogen, Kuslima ^e   Darzynkiewicz, Zbigniew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Ita Dental Clinic   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e Alfacell Corporation   (United States)

Author keywords

Alkaloid; Apoptosis; Bisbenzlisoquinoline; Mesothelioma; MicroRNAs; Nuclear factor kappaB; Reactive oxygen species; RNA interference

Indexed keywords

CEPHARANTHINE; RANPIRNASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN LNCAP; CELL STRAIN U937; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GROWTH RATE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PROMYELOCYTIC LEUKEMIA; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; TUMOR CELL LINE;

EID: 47949117680     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.6172     Document Type: Article

References (70)

1. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinetics 1988; 21:169-82.
2. Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonuclease. J Biol Chem 1991; 266:245-51.
3. Ardelt W, Lee HS, Randolph G, Viera A, Mikulski SM, Shogen K. Enzymatic characterization of onconase, a novel ribonuclease with anti-tumor activity. Protein Sci 1994; 3:137-47.
4. Mosimann SC, Ardelt W, James MNG. Refined 1.7Å X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with antitumor activity. J Mol Biol 1994; 236:1141-53.
5. Ardelt W, Shogen K, Darzynkiewicz Z. Onconase and amphinase, the anti-tumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 2008; (in press).
6. Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006; 28:1615-22.
7. Benito A, Ribo M, Vilanova M. On the track of antitumor ribonucleases. Mol BioSyst 2005; 1:294-302.
8. Lee JE and Raines RT. Ribonucleases as novel chemotheraupeutics: the ranpirnase example. BioDrugs 2008; 22:53-8.
9. Mikulski S, Viera A, Darzynkiewicz Z, Shogen K. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66:304-10.
10. Mikulski S, Viera A, Shogen K. In vitro synergism between a novel amphibian oocytic ribonuclease (ONCONASE) and tamoxifen, lovastatin and cisplatin in human OVCAR-3 ovarian carcinoma cell line. Int J Oncol 1992; 1:779-85.
11. Rybak SM, Pearson J, Fogler W, Volker K, Spence S, Newton DL, Mikulski SM, Ardelt W, Riggs C, Kung H, Longo D. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with ONCONASE, an antitumor ribonuclease. JNCI 1996; 88:747-53.
12. Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993; 268:10686-93.
13. Mikulski SM, Bernstein E, Ardelt W, Shogen K, Menduke K. Striking increase in survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. JNCI 1990; 82:151-3.
14. Lee I, Kalota A, Gewirtz AM, Shogen K. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 2007; 27:299-307.
15. Mikulski SM, Constanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-81.
16. Constanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnmase. Cancer Invest 2005; 23:643-50.
17. Vogelzang NJ, Porta C, Mutt L. New agents in the management of advanced mesothelioma. Semin Oncol 2005; 32:336-50.
18. Pavlakis N, Vogelzang NJ. Ranpirnase-an antitumor ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 2006; 6:1391-9.
19. Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003; 116:313-24.
20. Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ. Entry into cells and selective degradation of tRNA by a cytotoxic member of the RNase A family. J Biol Chem 2002; 277:15142-6.
21. Ardelt B, Ardelt W, Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2003; 2:22-4.
22. KIP and decreased pRb phosphorylation. Leukemia 1998; 12:1241-8.
23. Grabarek J, Ardelt B, Du L, Darzynkiewicz Z. Activation of caspases and serine proteases during apoptosis induced by onconase (Ranpirnase). Exp Cell Res 2002; 278:61-71.
24. Grabarek J, Ardelt B, Kunicki J, Darzynkiewicz Z. Detection of in situ activation of transglutaminase during apoptosis: correlation with the cell cycle phase by multiparameter flow- and laser scanning-cytometry. Cytometry 2002; 49:83-9.
25. Ardelt B, Ardelt W, Pozarowski P, Kunicki J, Shogen K, Darzynkiewicz Z. Cytostatic and cytotoxic properties of Amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes. Cell Cycle 2007; 6:3097-102.
26. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami Traganos F. Cytometry in cell necrobiology. Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27:1-20.
27. Mikulski SM, Viera A, Darzynkiewicz Z. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66:304-10.
28. Deptala A, Halicka HD, Ardelt W, Mikulski SM, Shogen K, Darzynkiewicz Z. Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 1998; 13:11-6.
29. Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z, Wu JM. Combined effects of onconase and IFNbeta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol 2002; 20:891-6.
30. Kim DH, Kim EJ, Kalota A, Gewirtz AA, Glickson J, Shogen H, Lee I. Possible mechanisms of improved response by cytotoxic RNase, Onconase, on 549 human lung cancer xenografts of nude mice. Adv Exp Biol Med 2007; 599:53-9.
31. Halicka HD, Murakami T, Papageorgio CN, Mittelman A, Mikulski SM, Shogen K, Darzynkiewicz Z. Induction of differentiation of leukemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates frequency of apoptosis triggered by onconase. Cell Prolif 2000; 33:407-17.
32. Halicka HD, Ardelt B, Shogen K, Darzynkiewicz Z. Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase. Int J Oncol 2007; 30:841-7.
33. Van Antwerp DJ, Martin SJ, Kafri T, Green DG, Verma IM. Suppression of TNFα-induced apoptosios by NFκB. Science 1996; 274:787-9.
34. Wang CY, Mayo MM, Baldwin AS Jr. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NFκB. Science 1996; 274:784-7.
35. Begg AA, Baltimore D. An essential role for NFκB in preventing TNFα induced cell death. Science 1996; 274:782-4.
36. Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock and inflammatory diseases. Life Sciences 2007; 80:1073-9.
37. Morita K, Nakamura M, Nagamachi M, Kishi T, Miyachi Y. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. J Dermatol 2002; 29:661-4.
38. Kimoto T, Suemitsu K, Nakayama H, Komori E, Ohtani M, Ando S. Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys blomhoffii) with low dose of antivenin: report of 43 consecutive cases. Nippon Geka Hokan 1997; 66:71-7.
39. Ohta T, Morita K. Effect of cepharanthin on radiotherapy induced leucopenia. Rinsho Hoshasen 1990; 35:471-4.
40. Chea A, Hout S, Bun SS, Tabatadze N, Gasquet M, Azas N, Elias R, Balansard G. Antimalarial activity of alkaloids isolated from Stephania rotunda. J Ethnopharmacol 2007; 12:132-7.
41. Goto M, Zeller WP, Hurley RM. Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats. J Pharm Pharmacol 1991; 43:589-91.
42. Sato T, Ohnishi ST. In vitro anti-sickling effect on cepharanthine. Eur J Pharmacol 1982; 83:91-5.
43. Shiraishi N, Arima T, Aono K, Inouye B, Morimoto Y, Utsumi K. Inhibition by biscoclaurine alkaloid of lipid peroxidation in biological membranes. Physiol Chem Physics 1980; 12:299-305.
44. Nakamura K, Tsuchiya S, Sugimoto Y, Sugimura Y, Yamada Y. Histamine release inhibition activity of bisbenzylisoquinoline alkaloids. Planta Medica 1992; 58:505-8.
45. Kohno H, Inoue H, Seyama Y, Yamashita S, Akasu M. Mode of the anti-allergic action of cepharanthine on an experimental model of allergic rhinitis. Nippon Yakurigaku Zasshi 1987; 90:205-11.
46. Fujimura T, Shibata H, Maekawa I, Furusawa S, Kawauchi H, Sasaki K, Takayanagi Y. Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells. Japan J Pharmacol 1990; 54:464-7.
47. Sato T, Morita I, Fujita H, Ono M, Kimishima A, Tomiyama J, Murota S. Pharmacological characterization of cepharanthin in chronic idiopathic thrombocytopenic purpura. Platelets 2001; 12:156-62.
48. Kip1. Anticancer Res 2003; 23:1441-8.
49. Yasukawa K, Takido M, Takeuchi M, Akasu M, Nakagawa S. Cepharanthine inhibits twostage tumor promotion by 12-O-tetradecanoylphorbol 13-acetate and mezerein on skin tumor formation in mice initiated with 7, 12-dimethylbenz[á] anthracene. J Cancer Res Clin Oncol 1991; 117:421-4.
50. Kogure K, Goto S, Abe K, Ohiwa C, Akasu M, Terada H. Potent antiperoxidation activity of the bisbenzylisoquinoline alkaloid cepharanthine: the amine moiety is responsible for its pH-dependent radical scavenge activity. Biochim Biophys Acta 1999; 1426:133-42.
51. Kogure K, Tsuchiya K, Abe K, Akasu M, Tamaki T, Fukuzawa K, Terada H. Direct radical scavenging by the bisbenzylisoquinoline alkaloid cepharanthine. Biochim Biophys Acta 2003; 1622:1-5.
52. Oyaizu H, Adachi Y, Yasumizu R, Ono M, Ikebukuru K, Fukuhara S, Ikahara S. Protection of T cells from radiation-induced apoptosis by Cepharantin. Int J Immunopharmacol 2001; 1:2091-9.
53. Halicka HD, Ita M, Tanaka T, Kurose A, Darzynkiewicz Z. The biscoclaurine alkaloid cepharanthine protects DNA in TK6 lymphoblastoid cells from constitutive oxidative damage. Pharmacol Rep 2008; 60:93-100.
54. Zhao H, Tanaka T, Halicka HD, Traganos F, Zarebski M, Dobrucki J, Darzynkiewicz Z. Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports the aging-related processes. Cytometry A 2007; 71:905-14.
55. Tamatami T, Azuma M, Motegi K, Takamaru N, Kawashima Y, Bando T. Cepharanthinenhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral carcinoma calls. Int J Oncol 2007; 31:761-8.
56. Ardelt B, Juan G, Burfeind P, Salomon T, Wu JM, Hsieh TC, Li X, Sperry R, Pozarowski P, Shogen K, Ardelt W, Darzynkiewicz Z. Onconase, an anti-tumor ribonuclease suppresses oxidative stress. Int J Oncol 2007; 31:663-9.
57. Jia YT, Ma B, Wei W, Xu Y, Wang Y, Tang HT, Xia ZF. Sustained activation of nuclear factorκB by reactive oxygen species is involved in the pathogenesis of stress-induces gastric damage in rats. Crit Care Med 2007; 35:1582-89.
58. Vile GF, Tanef-Ilitschew A, Tyrrel RM. Activation of NFkappaB in human skin fibroblasts by the oxidative stress generated by UVA radiation. Photochem Photobiol 1995; 62:463-8.
59. Barr J, Sharma CS, Sarkar S, Wise K, Dong L, Peryakaruppan A, Ramesh GT. Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol Cell Biochem 2007; 297:93-9.
60. Piette J, Piret B, Bonizzi G, Schoonbroodt S, Merville MP, Legrand-Poels S, Bours V. Multiple redox regulation in NFkappaB transcription factor activation. Biol Chem 1997; 378:1237-45.
61. Gorczyca W, Bruno S, Darzynkiewicz RJ, Gong J, Darzynkiewicz Z. DNA strand breaks occurring during apoptosis: Their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Oncol 1992; 1:639-48.
62. Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods 2008; 44:250-4.
63. Chou TC, Talalay P. Quantitative analysis of the dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 1984; 22:27-55.
64. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:11111-6.
65. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-105.
66. Li S, Blackburn EH. Expression and suppression of human telomerase RNA. Cold Spring Harb Symp Quant Biol 2006; 71:211-5.
67. Greider CW. Telomerase RNA levels limit the telomere length equilibrium Cold Spring Harb Symp Quant Biol 2006; 71:225-9.
68. Baldwin AS Jr. The NFκB and IκB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14:649-83.
69. Darzynkiewicz Z, Carter SP, Old LJ. Effect of recombinant tumor necrosis factor on HL-60 cells: cell cycle specificity and synergism with actinomycin D. J Cell Physiol 1987; 130:328-35.
70. Zingarelli N. Nuclear factorκB. Crit Care Med 2005; 33:414-6.